Open-label, Multicenter, Phase 1/2 Study of Mogamulizumab in Combination With Nivolumab in Subjects With Locally Advanced or Metastatic Solid Tumors

Trial Profile

Open-label, Multicenter, Phase 1/2 Study of Mogamulizumab in Combination With Nivolumab in Subjects With Locally Advanced or Metastatic Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Apr 2018

At a glance

  • Drugs Mogamulizumab (Primary) ; Nivolumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Kyowa Hakko Kirin
  • Most Recent Events

    • 27 Mar 2018 Status changed from recruiting to active, no longer recruiting.
    • 14 Feb 2018 Planned End Date changed from 1 Jul 2018 to 1 Oct 2018.
    • 14 Feb 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top